Latest news with #MZE829
Associated Press
29-05-2025
- Business
- Associated Press
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present a company overview at the Jefferies 2025 Global Healthcare Conference on Thursday, June 5, 2025 at 2 p.m. ET. A live webcast will be available in the Investors section of the company's website at and archived for 60 days following the presentation. About Maze Therapeutics Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company's pipeline is led by two wholly owned programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for patients. For more information, please visit or follow the company on LinkedIn and X. IR/Corporate Contact: Amy Bachrodt, Maze Therapeutics [email protected] Media Contact: Dan Budwick, 1AB [email protected]
Reuters
27-01-2025
- Business
- Reuters
Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO
Jan 27 (Reuters) - Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering, set to be the first U.S.-based biotech firm to debut this year. The South San Francisco, California-based company is seeking up to $132.6 million by offering 7.8 million shares priced between $15 and $17 each. The IPO could be one of the several offerings from the biotech sector in the coming weeks as a clutch of pharmaceutical companies looks to test investor appetite towards the industry. "Despite investors shying away from the sector since the election, we're still hopeful that easing monetary policy could provide a tailwind throughout the year," said IPOX research analyst Lukas Muehlbauer, adding the recent biotech IPO filings are a positive sign. Drug developers Aardvark Therapeutics, Aurion Biotech, Sonna Therapeutics, Metsera, and Odyssey Therapeutics are among the IPO hopefuls that have filed their paperwork in recent weeks. Maze, backed by healthcare venture firms ARCH Venture and Third Rock Ventures, as well as Alphabet's (GOOGL.O), opens new tab venture capital arm GV, raised $115 million in a funding round just over a month ago. The company is developing drugs to treat renal, cardiovascular and metabolic diseases. Maze's pipeline includes two lead experimental candidates for chronic kidney disease - MZE829, in a mid-stage study, and MZE782, in an early-stage study with initial data expected in the second half of 2025. The company is also developing MZE001, an experimental therapy to treat a rare muscle disorder Pompe disease, with Japan's Shionogi (4507.T), opens new tab, after a 2023 agreement for the therapy with French drugmaker Sanofi ( opens new tab fell apart due to U.S. Federal Trade Commission objections. J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities are the underwriters for the offering. Maze will list on the Nasdaq under the symbol "MAZE".
